Active ingredientTriflusalCat. No. P-T206-001CAS 322-79-2Family · Pharmaceutical analytical standards
Triflusal
An antiplatelet agent derived from acetylsalicylic acid, discovered and developed in Spain and on the market since 1981; it is used for secondary prevention of stroke and other cardiovascular events. This family brings together the active ingredient, pharmacopoeial impurities and labelled standards.
Did you know?It is almost identical to acetylsalicylic acid, differing only by a trifluoromethyl group on the benzene ring. In the body it is converted into HTB, a metabolite that is itself active.
Go to the active ingredient →Active ingredientTriflusalCat. No. P-T206-001CAS 322-79-2
Pharmacopoeial impurityTriflusal EP Impurity BCat. No. P-T206-002CAS 328-90-5
Isotopically labelledDesacetyl Triflusal-D3Cat. No. P-T206-003
Isotopically labelledTriflusal-d3Cat. No. P-T206-004CAS 2748541-63-9No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Reference substanceTriflusal CRSEDQM code T2005000Family TriflusalImpurityTriflusal impurity B CRSEDQM code T2005010Family TriflusalNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.